Resumption of DMARDs (n=9)* in the discontinuation group (n=13)
| Cancer treatment | Surgery only (n=3) | Chemotherapy (n=6) |
|---|---|---|
| DMARDs (before cancer diagnosis → resumption) | MTX+LEF → MTX | MTX+SSZ+HCQ → MTX |
| MTX+SSZ → ETA | MTX+LEF+HCQ → LEF+HCQ | |
| MTX+ADA → same | MTX+LEF+SSZ → LEF+HCQ | |
| MTX+SSZ+TC → MTX | ||
| MTX+HCQ → same | ||
| MTX+HCQ → LEF+HCQ |
DMARDs: disease modifying anti-rheumatic drugs, MTX: methotrexate, LEF: leflunomide, SSZ: sulfasalazine, HCQ: hydroxychloroquine, TC: tacrolimus, ETA: etanercept, ADA: adalimumab, IQR: interquartile range. *Time interval between discontinuation and resumption of DMARDs was median of 5.5 months (IQR 2.9, 18.3).